tbuckley/cabot-search huggingface dataset:
Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis
Authors: Lieve Van Hoovels, Sofie Schouwers, Stefanie Van den Bremt, Xavier Bossuyt
Journal: Annals of the Rheumatic Diseases (2018)

Figure 1 Fluorescence intensity (light intensity unit (LIU) or probability index (PI)) of antinuclear antibodies (ANA) by automated immunofluorescence assays (IFA).Three samples (sample 1: homogeneous 1:320; sample 2: fine speckled 1:80; sample 3: negative) were analysed by NOVA View (n=12: L1-L12), Image Navigator (n=2: L13-L14) or G-Sight (n=7: L15-L21).All laboratories used a screening dilution of 1:80 except for L17 that used a screening dilution of 1:40.All samples were diluted by a pipetting robot (QUANTA-Lyser, PhD, Sprinter, Zenit UP, Beeline, Helmed).For G-Sight, HEp-2000 or HEp-2 was used as substrate (as indicated).The cut-off for positivity was 49 LIU for NOVA View, 49 LIU for Image Navigator,<8 PI (negative) and >50 PI (positive) for G-Sight (L15-L17, L19-L21) or 20 PI for G-Sight (L18).All samples were run at least four times in different runs (the majority was determined at least eight times) according to the instructions of the manufacturer.The fluorescence intensity units (reported as LIU or PI) are shown.Statistical analysis of differences in fluorescence intensities between laboratories was evaluated by analysis of variance with Bonferroni correction for multiple comparisons.For NOVA View, there were significant differences between L1 versus L4 (p=0.044),L8 (p=0.001),L9 (p=0.002);L2 versus L8 (p=0.024) and L7 versus L8 (p=0.009),L9 (p=0.022) for sample 1, between L2 versus L4 (p=0.003),L8 (p=0.039),L9 (p=0.022);L7 versus L3 (p=0.034),L4 (p=0.026),L5 (p=0.033),L8 (p=0.003),L9 (p=0.018) and L11 versus L2 (p=0.022),L7 (p=0.007),L10 (p=0.005) for sample 2 and between L1 versus L4 (p=0.005),L8 (p=0.001),L11 (p=0.018) for sample 3.For G-Sight, there were differences between L15 versus L17 (p=0.001) and L16 versus L17 (p<0.001) for sample 1 and between L16 versus L17 (p=0.002) and L19 versus L21 (p=0.013) for sample 3. NOVA View estimates a pattern-specific end point titre based on the 1:80 screening dilution, a feature called single well titre.The single well titre varied between 1:160 and 1:640 for sample 1, between <1:80 and 1:320 for sample 2 and between <1:80 and 1:160 for sample 3.on July
Biomarkers Associated with Progression of Diabetic Kidney Disease: Do They Hold the Same Meaning for Blacks and Women?
Authors: LaTonya J. Hickson, Joyce E. Balls-Berry, Allan S. Jaffe, Andrew D. Rule
Journal: Journal of the American Society of Nephrology (2018)

We read with interest the study by Coca et al.,1 which examined the association of plasma TNF receptor-1 (TNFR-1), TNFR-2, and kidney injury molecule-1 (KIM-1) on renal outcomes in patients with type 2 diabetes mellitus. These investigations were performed on plasma samples from two previously conducted clinical trials involving patients with incident and progressive diabetic kidney disease (DKD) (n=1636). The findings support prior studies. In 2012, Niewczas et al.2 connected circulating markers of the proinflammatory cytokine (TNF-α) and the TNF pathway to the inflammatory state in DKD as a potential biomarker of DKD progression. These novel investigations (n=410) revealed the predictive capacity of plasma TNFR-1 and TNFR-2 in determining future DKD ESRD events. Since then, these studies have been replicated in predominantly white cohorts, with a few in other racial groups including American Indians and Chinese. One study by Chode et al.3 involved blacks (n=359), but it did not determine renal outcomes. In the study by Coca et al.,1 sampling was performed in only 293 (18%) blacks and 195 (12%; predominantly Veterans Affairs population) women. Race and sex were adjusted for in the statistical models. This, however, would not necessarily detect differences between populations either at baseline or over time. In many situations, race/ethnicity and sex have significant biologic effects on the measurement and interpretation of biomarkers. For example, recently, Bajaj et al.4 found significantly lower plasma levels of N-terminal pro-BNP (n=1998) in healthy blacks compared with whites in both sexes. On the basis of that and other studies, it now appears that clinical utilization of natriuretic peptides may benefit from race-specific thresholds. Are race or sex also important considerations in the interpretations needed of TNFR-1, TNFR-2, and KIM-1? In this study by Coca et al.,1 a stratified assessment by race and by sex may help inform whether TNFR levels necessitate race/sex specific thresholds for their interpretation. In particular, statistical models that assess for effect modification (statistical interaction) by race (or sex) on TNFRs and KIM-1 levels in predicting DKD ESRD events may be helpful. Ultimately, further studies in large cohorts more representative of different populations are needed. In their absence, persistence of studies with small samples sizes in these populations may not permit systematic reviews and meta-analyses to further elucidate race/sex differences. Disclosures A.S.J. either presently or in the past has consulted for Beckman Coulter Inc., Abbott Diagnostics, Siemens Healthcare Diagnostics Inc., Singulex, Sphingotec GmbH, Becton, Dickinson and Company, ET Healthcare Inc., Novartis, and Roche Diagnostics. All other authors have nothing to disclose.
A Tailored Letter Based on Electronic Health Record Data Improves Gestational Weight Gain Among Women With Gestational Diabetes Mellitus: The Gestational Diabetes’ Effects on Moms (GEM) Cluster-Randomized Controlled Trial
Authors: Monique M. Hedderson, Susan D. Brown, Samantha F. Ehrlich, Ai-Lin Tsai, Yeyi Zhu, Charles P. Quesenberry, Yvonne Crites, Assiamira Ferrara
Journal: Diabetes Care (2018)

Evaluate whether a tailored letter improved gestational weight gain (GWG) and whether GWG mediated a multicomponent intervention's effect on postpartum weight retention among women with gestational diabetes mellitus (GDM).
Alfie Evans case: Proposed law aims to prevent conflicts between parents and doctors
Authors: Clare Dyer
Journal: BMJ (2018)

Doctors, lawyers, ethicists, politicians, and parents are working on proposals to improve the way disputes between parents and doctors over children’s treatment are handled, after a series of bitter court battles have shown up problems with the current system.

The move was announced the day before Alfie Evans, the severely brain damaged boy at the centre of a fight between his parents and doctors, died in the early hours of Saturday 28 April at Liverpool’s Alder Hey Children’s Hospital, four and a half days after he was removed from the ventilator that was keeping him alive. Alfie, who would have had his second birthday on 9 May, had an undiagnosed neurodegenerative condition that had almost completely destroyed his brain.

Connie Yates, the mother of Charlie Gard, who died last July after an equally high profile court fight between his parents and Great …
CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).
Authors: Tanios S. Bekaii-Saab, Chung-Pin Li, Takuji Okusaka, Bert H. O'Neil, Michele Reni, Josep Tabernero, Shukui Qin, Eric Van Cutsem, Laura Borodyansky, Chiang Li
Journal: Journal of Clinical Oncology (2017)

TPS4148 Background: Cancer stem cells are considered to be fundamentally important for resistance to therapy, recurrence and metastasis. Napabucasin is a first-in-class cancer stemness inhibitor identified by its ability to inhibit STAT3-driven gene transcription and spherogenesis of cancer stem cells (Li et al, PNAS 112(6):1839, 2015). Preclinical studies suggest that napabucasin sensitizes heterogeneous cancer cells to chemotherapeutic agents, including nab-PTX and gem. Encouraging anticancer activity in mPDAC was observed in a phase Ib (El-Rayes et al, ASCO 2016) study of 37 pts, reporting 93% (28/30) disease control rate (DCR) and 50% (15/30) overall response rate (ORR), with 1 complete and 14 partial responses and prolonged disease control ( &gt; 24 wks) in 57% (17/30) of pts who have had a RECIST evaluation. On the basis of these data, a phase III trial is being conducted in North America, Europe, Australia and Asia. Methods: This study (ClinicalTrials.gov NCT02993731) will assess the efficacy of napabucasin+nab-PTX+gem vs nab-PTX+gem in pts with mPDAC (n = 1132). Pts must have been diagnosed with mPDAC &lt; 6 weeks prior to randomization and not have received treatment for metastatic disease. Pts are randomized in a 1:1 ratio to receive napabucasin 240 mg PO twice daily continuously plus nab-PTX+gem IV weekly for 3 out every 4 weeks, or nab-PTX+gem IV weekly for 3 out every 4 weeks. Pts will be stratified by geography, performance status and presence of liver metastases. Treatment will continue until disease progression, death, intolerability or patient/investigator decision to stop. Primary endpoint is overall survival (OS) in the general study population (HR 0.80 for OS improvement from 8.5 to 10.63 months); secondary endpoints include progression free survival (PFS), OS and PFS in the biomarker positive sub-population, ORR and DCR, safety and quality of life. In addition, blood and tumor archival tissue will be assessed for pharmacokinetic and biomarker analyses. Global enrollment is underway. Clinical trial information: NCT02993731.
Opioid Use Disorder After Self-medicating Pain From Traumatic Brain Injury
Authors: Thomas R. Kosten, David P. Graham, David A. Nielsen
Journal: JAMA Psychiatry (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo
Authors: Benjamin M Ellingson, Lauren E Abrey, Josep Garcia, Olivier Chinot, Wolfgang Wick, Frank Saran, Ryo Nishikawa, Roger Henriksson, Warren P Mason, Robert J Harris, Kevin Leu, Davis C Woodworth, Arnav Mehta, Catalina Raymond, Ararat Chakhoyan, Whitney B Pope, Timothy F Cloughesy
Journal: Neuro-Oncology (2018)

Abstract Background In the current study we used contrast-enhanced T1 subtraction maps to test whether early changes in enhancing tumor volume are prognostic for overall survival (OS) in newly diagnosed glioblastoma (GBM) patients treated with chemoradiation with or without bevacizumab (BV). Methods Seven hundred ninety-eight patients (404 BV and 394 placebo) with newly diagnosed GBM in the AVAglio trial (NCT00943826) had baseline MRI scans available, while 337 BV-treated and 269 placebo-treated patients had &gt;4 MRI scans for response evaluation. The volume of contrast-enhancing tumor was quantified and used for subsequent analyses. Results A decrease in tumor volume during chemoradiation was associated with a longer OS in the placebo group (hazard ratio [HR] = 1.578, P &lt; 0.0001) but not BV-treated group (HR = 1.135, P = 0.4889). Results showed a higher OS in patients on the placebo arm with a sustained decrease in tumor volume using a post-chemoradiation baseline (HR = 1.692, P = 0.0005), and a trend toward longer OS was seen in BV-treated patients (HR = 1.264, P = 0.0724). Multivariable Cox regression confirmed that sustained response or stable disease was prognostic for OS (HR = 0.7509, P = 0.0127) when accounting for age (P = 0.0002), KPS (P = 0.1516), postsurgical tumor volume (P &lt; 0.0001), O6-methylguanine-DNA methyltransferase status (P &lt; 0.0001), and treatment type (P = 0.7637) using the post-chemoradiation baseline. Conclusions The post-chemoradiation timepoint is a better baseline for evaluating efficacy in newly diagnosed GBM. Early progression during the maintenance phase is consequential in predicting OS, supporting the use of progression-free survival rates as a meaningful surrogate for GBM.
Changing landscape of HCV treatment in Germany: Data from a large real-world cohort 2014-2017
Authors: J. Petersen, K. Olah, T. Lorenzen, U. Stefan, C. Harder, K. Wursthorn, A. Plettenberg, B. Andre, M. Kathrin, A. Stoehr, P. Buggisch
Journal: Journal of Hepatology (2018)
Efficacy and safety of combination therapy with interferon and immunomodulators in entecavir-suppressed chronic hepatitis B patients (the endeavor study)
Authors: D. Wu, P. Wang, M. Han, Y. Chen, X.-Y. Chen, Q. Xia, C. Zhu, Q. Xie, J. Jiang, L. Wei, D. Tan, X. Dou, Y.-Y. Yu, J. Hou, Q. Ning
Journal: Journal of Hepatology (2018)
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation
Authors: William T. Abraham, Karl-Heinz Kuck, Rochelle L. Goldsmith, JoAnn Lindenfeld, Vivek Y. Reddy, Peter E. Carson, Douglas L. Mann, Benjamin Saville, Helen Parise, Rodrigo Chan, Phi Wiegn, Jeffrey L. Hastings, Andrew J. Kaplan, Frank Edelmann, Lars Luthje, Rami Kahwash, Gery F. Tomassoni, David D. Gutterman, Angela Stagg, Daniel Burkhoff, Gerd Hasenfuß
Journal: JACC Heart Failure (2018)

This study sought to confirm a subgroup analysis of the prior FIX-HF-5 (Evaluate Safety and Efficacy of the OPTIMIZER System in Subjects With Moderate-to-Severe Heart Failure) study showing that cardiac contractility modulation (CCM) improved exercise tolerance (ET) and quality of life in patients with ejection fractions between 25% and 45%.CCM therapy for New York Heart Association (NYHA) functional class III and IV heart failure (HF) patients consists of nonexcitatory electrical signals delivered to the heart during the absolute refractory period.A total of 160 patients with NYHA functional class III or IV symptoms, QRS duration <130 ms, and ejection fraction ≥25% and ≤45% were randomized to continued medical therapy (control, n = 86) or CCM (treatment, n = 74, unblinded) for 24 weeks. Peak Vo2 (primary endpoint), Minnesota Living With Heart Failure questionnaire, NYHA functional class, and 6-min hall walk were measured at baseline and at 12 and 24 weeks. Bayesian repeated measures linear modeling was used for the primary endpoint analysis with 30% borrowing from the FIX-HF-5 subgroup. Safety was assessed by the percentage of patients free of device-related adverse events with a pre-specified lower bound of 70%.The difference in peak Vo2 between groups was 0.84 (95% Bayesian credible interval: 0.123 to 1.552) ml O2/kg/min, satisfying the primary endpoint. Minnesota Living With Heart Failure questionnaire (p < 0.001), NYHA functional class (p < 0.001), and 6-min hall walk (p = 0.02) were all better in the treatment versus control group. There were 7 device-related events, yielding a lower bound of 80% of patients free of events, satisfying the primary safety endpoint. The composite of cardiovascular death and HF hospitalizations was reduced from 10.8% to 2.9% (p = 0.048).CCM is safe, improves exercise tolerance and quality of life in the specified group of HF patients, and leads to fewer HF hospitalizations. (Evaluate Safety and Efficacy of the OPTIMIZER System in Subjects With Moderate-to-Severe Heart Failure; NCT01381172).
Caspase-cleaved cytokeratin-18 (M30) and ActiTest predict hepatic inflammation in asymptomatic patients with alcoholic liver disease
Authors: K.H. Thorhauge, M. Thiele, B.S. Madsen, J.F. Hansen, S. Detlefsen, S. Antonsen, L.M. Rasmussen, A. Krag
Journal: Journal of Hepatology (2018)
Preoperative biliary drainage reverses cholestasis-associated inflammatory and fibrotic gene signatures in patients with perihilar cholangiocarcinoma
Authors: R. van Golen, M. Reiniers, L. de Haan, R. Weijer, J. Wiggers, A. Jongejan, P. Moerland, L. Alles, A. van Kampen, T. van Gulik, M. Heger
Journal: Journal of Hepatology (2018)
Long-term impact of HCV eradication after all-oral therapy in patients with clinical significant portal hypertension
Authors: S. Lens, E. Alvarado, Z. Mariño, J. Martinez, M.-C. Londoño, E. Llop, J.I. Fortea, L. Ibañez, R. Bañares, A. Puente, A. Albillos, José L.C. Panero, X. Torras, A. Baiges, V. Hernandez-Gea, J. Bosch, C. Villanueva, X. Forns, J.-C. Garcia-Pagan
Journal: Journal of Hepatology (2018)
Peroral endoscopic myotomy as a versatile approach to treating complex esophageal disorders
Authors: Antonella Putignano, Marc Barthet, Ricardo Rio-Tinto, Guido Costamagna, Hubert Louis, Vincent Huberty, Arnaud Lemmers, Jacques Devière
Journal: Endoscopy (2018)

Since 2008, peroral endoscopic myotomy (POEM) has evolved as a technique for managing esophageal achalasia [1]. POEM has also recently emerged as a potential therapeutic tool in treating other esophageal motility disorders [2] [3], including Jackhammer esophagus and Zenker’s diverticulum [4]. However, for mid or lower esophageal diverticulum, the surgical treatment is still recommended, despite being associated with high morbidity. In this video case we report the application of the POEM technique as a therapeutic approach in a patient affected by Jackhammer esophagus, distal esophageal spasm, and a large distal esophageal diverticulum ([Fig. 1], [Fig. 2 a]).
Sensory Impairments in Heart Failure—Are We Missing the Basics?
Authors: Madeline R. Sterling, Ariel F. Silva, Mary E. Charlson
Journal: JAMA Internal Medicine (2018)

This Teachable Moment examines the case of an 81-year-old man with heart failure (HF) who had been prescribed a regimen of therapies for comorbities but did not understand medication instructions owing to sensory impairments and subsequently experienced HF exacerbations due to noncompliance.
Common dental diseases in children and malocclusion
Authors: Jing Zou, Mingmei Meng, Clarice S Law, Yale Rao, Xuedong Zhou
Journal: International Journal of Oral Science (2018)

Abstract Malocclusion is a worldwide dental problem that influences the affected individuals to varying degrees. Many factors contribute to the anomaly in dentition, including hereditary and environmental aspects. Dental caries, pulpal and periapical lesions, dental trauma, abnormality of development, and oral habits are most common dental diseases in children that strongly relate to malocclusion. Management of oral health in the early childhood stage is carried out in clinic work of pediatric dentistry to minimize the unwanted effect of these diseases on dentition. This article highlights these diseases and their impacts on malocclusion in sequence. Prevention, treatment, and management of these conditions are also illustrated in order to achieve successful oral health for children and adolescents, even for their adult stage.
13C-methacetin breath test is a highly accurate non-invasive point of care test for detecting CSPH in patients with NASH
Authors: J. Bosch, C. Bureau, N. Chalasani, E. Lawitz, M. Abdelmalek, M. Rinella, S. Harrison, A. Berzigotti, A. Sanyal, M. Noureddin, D. Rockey, T.I. Ber, Y. Ilan, G. Garcia-Tsao
Journal: Journal of Hepatology (2018)
The widespread use of topical antimicrobials enriches for resistance in<i>Staphylococcus aureus</i>isolated from patients with atopic dermatitis
Authors: C.P. Harkins, M.A. McAleer, D. Bennett, M. McHugh, O.M. Fleury, K.A. Pettigrew, K. Oravcová, J. Parkhill, C.M. Proby, R.S. Dawe, J.A. Geoghegan, A.D. Irvine, M.T.G. Holden
Journal: British Journal of Dermatology (2018)

Carriage rates of Staphylococcus aureus on affected skin in atopic dermatitis (AD) are approximately 70%. Increasing disease severity during flares and overall disease severity correlate with increased burden of S. aureus. Treatment in AD therefore often targets S. aureus with topical and systemic antimicrobials. To determine whether antimicrobial sensitivities and genetic determinants of resistance differed in S. aureus isolates from the skin of children with AD and healthy child nasal carriers. In this case–control study, we compared S. aureus isolates from children with AD (n = 50) attending a hospital dermatology department against nasal carriage isolates from children without skin disease (n = 49) attending a hospital emergency department for noninfective conditions. Using whole genome sequencing we generated a phylogenetic framework for the isolates based on variation in the core genome, then compared antimicrobial resistance phenotypes and genotypes between disease groups. Staphylococcus aureus from cases and controls had on average similar numbers of phenotypic resistances per isolate. Case isolates differed in their resistance patterns, with fusidic acid resistance (FusR) being significantly more frequent in AD (P = 0·009). The genetic basis of FusR also differentiated the populations, with chromosomal mutations in fusA predominating in AD (P = 0·049). Analysis revealed that FusR evolved multiple times and via multiple mechanism in the population. Carriage of plasmid‐derived qac genes, which have been associated with reduced susceptibility to antiseptics, was eight times more frequent in AD (P = 0·016). The results suggest that strong selective pressure drives the emergence and maintenance of specific resistances in AD.
Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen
Authors: Grant W. Reed, Mouin S. Abdallah, Mingyuan Shao, Kathy Wolski, Lisa Wisniewski, Neville Yeomans, Thomas F. Lüscher, Jeffrey S. Borer, David Y. Graham, M. Elaine Husni, Daniel H. Solomon, Peter Libby, Venu Menon, A. Michael Lincoff, Steven E. Nissen
Journal: Journal of the American College of Cardiology (2018)